Analyst consensus rating
Aardvark Therapeutics Analyst Rating: Buy
Direct answer
Aardvark Therapeutics's consensus rating is Buy.
8 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $7.50.
Forecast evidence checked November 8, 2026.
Get free Aardvark Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.17
- Average price target
- $7.50
- High price target
- $28.00
- Low price target
- $1.50
- Low target gap
- +28.2%
- Target upside
- +541%
- High target gap
- +2,293.2%
- Target range width
- 2,265%
- Consensus rating
- Buy
- Analysts
- 8
- Evidence date
- November 8, 2026
- Valid through
- November 15, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Aardvark Therapeutics?
Aardvark Therapeutics has a verified Buy consensus. The same dataset has an average price target of $7.50.
How far are Aardvark Therapeutics's low and high targets from the recorded price?
The low target implies +28.2%, while the high target implies +2,293.2%.
How many analysts are included in Aardvark Therapeutics's consensus?
The verified consensus includes 8 analysts.
How is Aardvark Therapeutics's target upside or downside calculated?
The average target of $7.50 is divided by the recorded price of $1.17, then one is subtracted to produce +541%. This does not guarantee a future return.
When was Aardvark Therapeutics's analyst forecast verified?
The data was verified on 2026-11-08. The dataset is valid through 2026-11-15.